PDS Biotechnology Appoints Lars Boesgaard To Succeed Matthew Hill As CFO
(RTTNews) - Immunotherapy company PDS Biotechnology Corp. (PDSB) announced Tuesday the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023.
Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech's CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors.
Boesgaard has had a career spanning more than 25 years in healthcare and has deep capital markets and investor relations experience with global clinical and commercial-stage pharmaceutical and biotechnology companies.
Prior to joining PDS Biotech, Boesgaard served as CFO of AM-Pharma B.V. from September 2021 to August 2023. He also served as CFO of Columbia Care from August 2018 to August 2021.
Boesgaard was also previously the Vice President, CFO of Roka Bioscience from November 2015 to July 2018 and held several other senior finance positions with publicly traded companies including Insulet Corp., Alexion Pharmaceuticals and Novo Nordisk A/S.
DAX Modestly Higher As Investors Focus On Earnings
European Shares Mostly Higher In Cautious Trade; FTSE 100 Underperforms
Asian Shares Mostly Lower Ahead Of Trump-Putin Summit
Australian Dollar Advances On Robust Employment Data
Yen Rises Amid BoJ Rate Hike Expectation
Australian Dollar Advances Against Some Majors
European Shares Seen Mixed As Focus Shifts To US-Russia Talks
